Net sales for the period were SEK 34.1 million (27.7), an increase of 23 per cent, of which SEK 17.3 million (18.6) in the second quarter.
The operating loss for the period was SEK -3.7 million (-5.0) and for the second quarter SEK -2.8 million (-0.3).
Earnings per share for the period were SEK -0.17 (-0.22).
Cash and cash equivalents amounted to SEK 8.8 million at the end of the period.
The company was listed on First North on 28 May.
A new subsidiary was established in Canada.
Four systems were installed at the Karolinska University Laboratory.
Significant events after the close of the reporting period
There was a preview of the new application for body fluids in the USA in July.
Johan Wennerholm was employed as Chief Financial Officer.
|
CellaVision in summary |
|
|
|
(SEK m)
|
|
1 jan-30 june 2007
|
1 jan-30 june 2006
|
Full year 2006
|
|
Net sales |
34.1 |
27.7 |
54.8 |
|
Gross profit |
19.8 |
15.4 |
32.0 |
|
Operating loss |
-3.7 |
-5.0 |
-8.6 |
|
Net profit |
-3.9 |
-5.2 |
-8.8 |
|
Cash flow |
-8.0 |
-0.3 |
-0.8 |
CEO's comments
"Up to and including the second quarter CellaVision has delivered a total of 300 systems to customers, mainly in Europe and North America. The initiative in Canada with our own company has attracted great attention to our products, and the number of identified potential customers exceeds expectations. The new body fluid analysis application also generated great interest when it was shown at the international AACC Annual Meeting and Clinical Lab Expo in San Diego, USA in July," says Yvonne Mårtensson, CEO of CellaVision AB.
"The company's listing on First North has been completed and was well received. With continued good growth I look forward with confidence to achieving profitability in our core business - the hematology market."
Yvonne Mårtensson
CEO CellaVision AB
For more information, please contact:
Interim report for the period Jan - June 2007